Alzheimer's disease (AD) is a multifactorial neurodegenerative disease, with a complex pathogenesis and an irreversible course. Therefore, the early diagnosis of AD is particularly important for the intervention, prevention, and treatment of the disease. Based on the different pathophysiological mechanisms of AD, the research progress of biofluid biomarkers are classified and reviewed. In the end, the challenges and perspectives of future research are proposed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039951 | PMC |
| http://dx.doi.org/10.3389/fnagi.2024.1380237 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing 17β-estradiol and progesterone concentrations in young, physically active females: Insights from plasma versus serum analysis.
Exp Physiol
March 2025
Women in Sport Research and Innovation Hub, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
Serum measurements of 17β-estradiol and progesterone are widely used to verify menstrual cycle status and confirm contraceptive use, often through commercially available immunoassay kits. However, no studies have investigated whether blood collection tube chemistries influence hormone concentrations in young females, despite assays permitting the use of different biofluids with similar reference ranges. In this study, venous blood was sampled from physically active females (n = 25) using Ethylenediaminetetraacetic acid (EDTA) and serum vacutainers, and 17β-estradiol and progesterone concentrations were measured using competitive immunoenzymatic assays.
View Article and Find Full Text PDFComprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders.
Mol Neurodegener
March 2025
Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Background: Therapeutic development for frontotemporal dementia (FTD) is hindered by the lack of biomarkers that inform susceptibility/risk, prognosis, and the underlying causative pathology. Blood glial fibrillary acidic protein (GFAP) has garnered attention as a FTD biomarker. However, investigations of GFAP in FTD have been hampered by symptomatic and histopathologic heterogeneity and small cohort sizes contributing to inconsistent findings.
View Article and Find Full Text PDFPilot Study of Metabolomic Biomarkers Associated with Outcomes in Patients with Lung Cancer Undergoing Radiation Therapy.
J Proteome Res
March 2025
Department of Radiation Oncology, The Ohio State University, Columbus, Ohio 43210, United States.
Lung cancer stands as the leading cause of cancer-related death worldwide, impacting both men and women in the United States and beyond. Radiation therapy (RT) serves as a key treatment modality for various lung malignancies. Our study aims to systematically assess the prognosis and influence of RT on metabolic reprogramming in patients diagnosed with nonsmall-cell lung cancer (NSCLC) through longitudinal metabolic profiling.
View Article and Find Full Text PDFToward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities.
Nucleic Acids Res
February 2025
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain.
RNA molecules have garnered increased attention as potential clinical biomarkers in recent years. While short-read sequencing and quantitative polymerase chain reaction have been the primary methods for quantifying RNA abundance, they typically fail to capture critical post-transcriptional regulatory elements, such as RNA modifications, which are often dysregulated in disease contexts. A promising cutting-edge technique sequencing method that addresses this gap is direct RNA sequencing, offered by Oxford Nanopore Technologies, which can simultaneously capture both RNA abundance and modification information.
View Article and Find Full Text PDFSingle extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson's disease.
Cell Rep Med
March 2025
Nuffield Department of Clinical Neurosciences & Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK. Electronic address:
Accurate diagnosis of early Parkinson's disease requires platforms suitable for detecting minute amounts of neuronally derived biomarkers in the massive protein excess of easily accessible biofluids such as blood. Here, we describe an on-chip droplet-confined fluorescence reporting assay that identified α-synuclein on the membrane of L1CAM+ extracellular vesicles (EVs) immunocaptured from human serum and corroborate this finding by super-resolution direct stochastic optical reconstruction microscopy (dSTORM) microscopy. Using conditioned media from neuroblastoma cells expressing α-synuclein mutants or patient-derived induced pluripotent stem cell (iPSC) neurons with α-synuclein gene triplication, we found that association of α-synuclein with the L1CAM+ EV surface is increased under pathological conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!